CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins76% CONFIDENCEOverall confidence: 76%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
GSK's[1] press release states the FDA approval; the 23 October 2025 date is given by Pharmaceutical Executive's 24 October article and by a search summary of GSK's announcement, and the PharmaLetter[4] calls it a re-approval.On 23 October 2025 the US FDA approved Blenrep with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior lines of therapy.
1.00